Salcut-NH2: A Novel Target for Development of Anti-Tumorigenic, Anti-Angiogenic Therapeutics and Diagnostics
Posted May 04 2009 5:00pm
Description of Invention: Salcut-NH2, a novel amidated peptide derived from the Apelin proprotein, is shown to induce the proliferation of cells. Uncontrolled cell proliferation is the salient feature of cancer. Thus, therapeutics that stop this aberrant cell division are very desirable. Salcut-NH2 can be the basis for developing novel inhibitors of cancer growth such as modified peptide antagonists like salcut-glycine (salcut-Gly). Alternately, salcut-NH2 could be the target of antibody therapies that block its activity. In some instances, such as wound healing, inducing cell proliferation would be advantageous. It also has been demonstrated that salcut-NH2 induces angiogenesis so it may also have application as a topically administered therapeutic for speeding the healing of skin wounds. Finally, increasing levels of salcut-NH2 in body fluids may be reflective of disease progression. A diagnostic kit for salcut-NH2 could potentially be developed for the prognosis of a variety of diseases associated with aberrant cell proliferation or angiogenesis.
Development of therapeutics that inhibit cancer growth or diseases related to aberrant angiogenesis
Topical therapeutic to hasten wound healing
Diagnostic for the prognosis of cancer or diseases related to aberrant growth of blood vessels
Naturally derived peptide and thus negligible immunogenicity
Amidation makes salcut-NH2 resistant to proteases and increases its availability
Small peptides are readily excreted facilitating measurement of salcut-NH2 for diagnostic purposes
Development Status: Early stage; pre-clinical data available.
Collaborative Research Opportunity: The National Cancer Institute Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 1) Identification of new biological functions for Salcut-NH2 or 2) Development of compounds that suppress or augment Salcut-NH2 bioactivity. Please contact John D. Hewes, Ph.D. at 301-435-3121 or email@example.com for more information.
Portfolios: Cancer Cancer - Diagnostics Cancer - Therapeutics Ophthalmology Ophthalmology - Therapeutics
For Additional Information Please Contact: Surekha Vathyam Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4076 Fax: 301-402-0220